In the press
Redbiotec is a privately held biopharmaceutical company located in Zurich-Schlieren, Switzerland. Redbiotec develops immunotherapies against herpes and cancer.
We are happy to keep you informed about the latest developments. To subscribe to our newsletter, please send an email to firstname.lastname@example.org.
We are pleased with the global media coverage of the acquisition of our spin-off company Redvax GmbH by Pfizer Inc.. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.
Coverage of “Pfizer-Redvax deal” by selected media: